Insilico Medicine’s VAC platform makes biological age a core variable as it attempts to model cellular change across six biological scales. #longevity# #geroscience# #insilico# #biologicalage# #cellularreprogramming#

InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug’ With AI—“The best way to compete with China is to compete in China. Otherwise, you’re going to lose the biggest market that the world will ever see.” @jasonchau9903

Did some analysis on which Hyperliquid front end has the most profitable users: 🥇 HyperDash 🥈 Insilico 🥉 Rabby Chart is percent of traders that are net profitable after a year.

HypurrCo gathers. 8 Oct 2026, Singapore. Only made possible with our incredible sponsors/partners @HyperliquidPC, @HypeStrat, @InsilicoTrading, @nansen_ai, @chainlink, @eliospay, @hyperbeat, @wintermute_t, @hyperlendx, @talistrade, @hyperlink_xyz @tread_fi, Velar Tech, @ValantisLabs, @HypernovaX, @liquidtrading, @21shares Venue will be announced closer to the event. RSVP here:

We're doing it again 🫡 HypurrCo Gathers is coming back on Token2049 with our title sponsors @HyperliquidPC , @HypeStrat and @InsilicoTrading. Details Wednesday, 8 October 11am–3pm Bugis Area, Singapore (exact location to be revealed day before) If you're an ecosystem builder, investor, or partner, we'd love to have you there. HypurrCo Gathers are free, community-run events with no pitch-decks. What's in store for attendees? • Panels • Merch • Networking • Great vibes Speaker line-up and more information will drop over the next few weeks. We can't wait to show you what we have in store :) RSVP here - Invite is subject to approvals only, with a maximum capacity of one rep per team to ensure a high quality event:

At The World Artificial Intelligence Conference (#WAIC#) in Shanghai, #TencentCloud# hosted the “Agent in Action: From Pilots to Real-World Impact” panel with leaders from Decathlon, MiniMax, Insilico Medicine, SMG, and DANA. #DANA’s# Chief Innovation Officer Darrick Rochili shared how #AI# agents are transforming financial services — from engineering and customer support to real-time risk management and credit decisioning. Thank you to all speakers for the inspiring discussion. Watch the full video for Darrick’s in-depth insights and key takeaways!

#AI4S# is back in focus. $MRNA's historic Phase 3 cancer vaccine win reignited interest in how AI and data could reshape biotech. In Hong Kong, #DiagensTech# (HKEX: 2526) is gaining attention. H1 revenue rose 21% YoY, while model-service revenue jumped 101%, now accounting for 87% of total revenue. Other AI4S names in focus include #InsilicoMedicine# (HKEX: 3696) and #XtalPi# (HKEX: 2228). All are tradable on StableStock. → Not investment advice. For informational purposes only.

Why Generic Humanoid Robots Will Fail — And What's Next Imagine an alternate world where we never invented the car. In that world, a robotics engineer might reasonably conclude that robotic horses are the future — replace the living ones, keep the stables and saddles, ride them to work. Convenient, modern, and the roads stay free of manure. It sounds absurd only because you already know about cars. We keep making the same mistake with humanoid robots. Consider transportation. To finally make driving safe, we had two options: put a humanoid in the driver's seat, or embed sensing and compute directly into the vehicle. Waymo chose the latter. It has no steering wheel. It exists purely to move people efficiently from A to B. The humanoid was not needed. Consider a sock factory. Yes, you could replace workers with humanoid robots one-for-one on the assembly line — and gain maybe 2-3x efficiency. Or you could completely redesign the workflow around a purpose-built autonomous sewing system and eliminate most of the factory, the chairs, the cafeteria, the manual sewing machines, the HVAC, the doors, and the restrooms. The actual optimization is to side-step the previous human-imposed physical constraint. Look at Ukraine. The front lines aren't filling up with Terminator-style humanoids carrying rifles. Human soldiers are being replaced by heterogeneous swarms of purpose-specific drones: some for reconnaissance, some for logistics, some for delivering munitions. War is being restructured around the desired outcome (survival), not the soldier's shape. Consider a 1970's office. Want to move information through teams of people? We once used typists, paper, trucks to supply the paper, typewriters, and repair technicians. A linear improvement would have been to replace the human typist with a 10-fingered humanoid. What actually happened? The entire workflow — paper, printers, typewriter factories, delivery trucks, the desks, the offices — was obliterated. Email deleted the human clerk's entire universe. Consider cancer early detection by mammography. Today, getting a mammogram requires expensive hardware, logistics infrastructure, human nurses and doctors, a biopsy workflow, a human pathologist with a microscope (imported from Germany or Japan), a written finding, multiple physician reviews. Sure, you could replace the pathologist with a humanoid (the microscope focus knob requires finger dexterity) and get a modest efficiency gain (and faster responses at 2 am). Or — the far more likely future — we all swallow a cancer detection pill every few months, and 24 hours later a color-changing sticker on our arm turns red or green. No hardware. No hospital. No logistics. No pathologist. No office. No desk. No humanoid. The workflow isn't optimized by a literal drop-in swap of a human pathologist for a humanoid. The entire workflow simply ceases to exist. Consider life sciences research and drug development. We're seeing excitement about robot arms and humanoids pipetting water in research labs. Robot horses, episode 7. We don't design aircraft by crashing test planes — we simulate them entirely in software first. Biology will go the same way. The path to scalable drug discovery isn't robot arms in conventional wet labs demonstrating 10 fingered prowess in manipulating Eppendorf tubes filled with purple food coloring. Rather, we need in-silico biological models that evaluate billions of hypotheses computationally, with physical manipulation of atoms only at the very end. The clear pattern. Efficient automation doesn't try to replicate a 10-fingered human in a static context. Automation eliminates physical rate-limiting steps in their entirety. That's why "classical" humanoid robots, as a generic category, will largely fail. They're robotic horses. They assume the infrastructure and workflows stay fixed and only the 10-fingered human is swapped out. That's not how economic and technological pressure works. What actually matters? If humans continue to inhabit the physical world, then moving atoms will remain important, and that requires five things: atoms, energy, force generation and actuation, sensing, and compute. Everything else — form factor, number of limbs, type of end effector — is a variable to be optimized for the task. So if you are a pathologist, a robotics engineer, a teacher, a parent, a politician, or a sewing factory owner - please think different. Most obviously, we should all anticipate, and build for, a future in which robots exhibit extreme physical fluidity: Two arms or four. Wheels or legs. Tentacles or flippers. Three fingers or twelve, or none at all. Eyes at the front, side, or tip of a tentacle. At OpenMind, we don't care what you look like right now - we got you, in all your physical form factors. OM2 ships in July, for all machines. Let's build.